Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
R-MEGACHOP
- Development stage
- Unknown
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
R-MEGACHOP is a high-dose, dose-dense variant of the standard R-CHOP chemotherapy regimen used in the treatment of aggressive B-cell non-Hodgkin lymphoma, particularly diffuse large B-cell lymphoma (DLBCL). Like standard R-CHOP, it combines rituximab (a monoclonal antibody targeting CD20 on B cells), cyclophosphamide (an alkylating agent), doxorubicin (an anthracycline antibiotic), vincristine (a vinca alkaloid), and prednisone or prednisolone (a corticosteroid). The "Mega" designation refers to increased doses and/or shortened intervals between cycles compared to conventional regimens. The goal is to intensify therapy for high-risk patients. However, clinical studies have shown that increasing the dose intensity with regimens like R-MegaCHOP does not significantly improve outcomes compared to standard dose-dense approaches but does increase toxicity[6].
- Brand names
- R-MEGACHOP
- Other names
- R-MegaCHOPRituximab plus MegaCHOPHigh-dose R-CHOP
02
Targets
CD20 (B-lymphocyte antigen CD20)DNAGR (Glucocorticoid receptor)TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on R-MEGACHOP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on R-MEGACHOP.